2025 Global Medical Device Top 100 Rankings Released: Medtronic and Johnson & Johnson Continue to Lead, Mindray and MicroPort Make the List

Deep News
2025/09/19

On September 18, the medical device industry website Medical Design & Outsourcing published the 2025 Global Medical Device Company Top 100 Rankings (Medtech Big 100). Among the top ten positions, American companies continue to maintain absolute dominance: Medtronic PLC and Johnson & Johnson MedTech retained their first and second positions respectively; Medline Industries surpassed Siemens Healthineers to rise to third place; Boston Scientific climbed 2 positions to 9th place; BD Medical (Medical and Interventional business) advanced from 12th to 10th position.

Two Chinese companies made this year's rankings:

Mindray Medical Ranking: 25th (↑2) Revenue: $5.01 billion (fiscal year ending December 31, 2024) R&D Investment: $557 million

As China's leading medical device company, Mindray Medical delivered its first interim report showing both revenue and net profit declines since its A-share listing in 2018 for the first half of 2025: revenue of RMB 16.743 billion, down 18.45% year-over-year; attributable net profit of RMB 5.069 billion, down 32.96% year-over-year. Market sources indicate that Mindray is considering a secondary listing in Hong Kong, seeking to raise at least $1 billion, with HTSC and JPMorgan Chase already selected as underwriters.

MicroPort Medical Ranking: 70th (↑3) Revenue: $1.03 billion (fiscal year ending December 31, 2024) R&D Investment: $217 million

MicroPort Medical achieved a key turnaround in the first half of 2025: under non-Hong Kong Financial Reporting Standards, the company recorded an adjusted profit of $1.221 million, compared to a loss of $64.074 million in the same period last year; EBITDA reached $128 million, up 116.2% year-over-year; first-half losses narrowed to $46.6 million (compared to $96.83 million in the same period last year). On the day of the earnings announcement, the company's stock price surged 19.57% in the afternoon session. The performance improvement was primarily attributed to strong overseas market performance, with overseas revenue growing 85% year-over-year in 2024.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10